Synthesis, antitumor activity, and molecular docking study of 2-cyclopentyloxyanisole derivatives: mechanistic study of enzyme inhibition

References

• (a) Avendańo C, Menéndez J. Medicinal chemistry of anticancer agents. Amsterdam: Elsevier; 2008.
   Google Scholar
  (b) Varmus H. The new era in cancer research. Science 2006;312:1162–5.
   PubMed Web of Science ®Google Scholar
  (c) Eckhardt S. Recent progress in the development of anticancer agents. Curr Med Chem Anticancer Agents 2002;2:419–39.
   PubMedGoogle Scholar
• (a) El-Azab AS, Al-Omar MA, Abdel-Aziz AAM, et al. Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: molecular docking study. Eur J Med Chem 2010;45:4188–98.
   PubMed Web of Science ®Google Scholar
  (b) Al-Suwaidan IA, Alanazi AM, Abdel-Aziz AAM, et al. Design, synthesis and biological evaluation of 2-mercapto-3-phenethylquinazoline bearing anilide fragments as potential antitumor agents: molecular docking study. Bioorg Med Chem Lett 2013;23:3935–41.
   PubMed Web of Science ®Google Scholar
  (c) Alanazi AM, Al-Suwaidan IA, Abdel-Aziz AAM, et al. Design, synthesis and biological evaluation of some novel substituted 2-mercapto-3-phenethylquinazolines as antitumor agents. Med Chem Res 2013;22:5566–77.
   Web of Science ®Google Scholar
• (a) Alanazi AM, Abdel-Aziz AAM, Al-Suwaidan IA, et al. Design, synthesis and biological evaluation of some novel substituted quinazolines as antitumor agents. Eur J Med Chem 2014;79:446–54.
   PubMed Web of Science ®Google Scholar
  (b) Alanazi AM, Abdel-Aziz AAM, Shawer TZ, et al. Synthesis, antitumor and antimicrobial activity of some new 6-methyl-3-phenyl-4(3H)-quinazolinone analogues: in silico studies. J Enzyme Inhib Med Chem 2016;31:721–35.
   PubMed Web of Science ®Google Scholar
  (c) El-Azab AS, Al-Dhfyan A, Abdel-Aziz AAM, et al. Synthesis, anticancer and apoptosis-inducing activities of quinazoline–isatin conjugates: epidermal growth factor receptor-tyrosine kinase assay and molecular docking studies. J Enzyme Inhib Med Chem 2017;32:935–44.
   PubMed Web of Science ®Google Scholar
• (a) Mohamed MA, Ayyad RR, Shawer TZ, et al. Synthesis and antitumor evaluation of trimethoxyanilides based on 4(3H)-quinazolinone scaffolds. Eur J Med Chem 2016;112:106–13.
   PubMed Web of Science ®Google Scholar
  (b) Al-Suwaidan IA, Abdel-Aziz AAM, Shawer TZ, et al. Synthesis, antitumor activity and molecular docking study of some novel 3-benzyl-4(3H)quinazolinone analogues. J Enzyme Inhib Med Chem 2016;31:78–89.
   PubMed Web of Science ®Google Scholar
  (c) El-Azab AS, Abdel-Aziz AAM, Ghabbour HA, et al. Synthesis, in vitro antitumour activity, and molecular docking study of novel 2-substituted mercapto-3-(3,4,5-trimethoxybenzyl)-4(3H)-quinazolinone analogues. J Enzyme Inhib Med Chem 2017;32:1229–39.
   PubMed Web of Science ®Google Scholar
• (a) Abdel-Aziz AAM. Novel and versatile methodology for synthesis of cyclic imides and evaluation of their cytotoxic, DNA binding, apoptotic inducing activities and molecular modeling study. Eur J Med Chem 2007;42:614–26.
   PubMed Web of Science ®Google Scholar
  (b) El-Azab AS, Alanazi AM, Abdel-Aziz NI, et al. Synthesis, molecular modeling study, preliminary antibacterial, and antitumor evaluation of N-substituted naphthalimides and their structural analogues. Med Chem Res 2013;22:2360–75.
   Web of Science ®Google Scholar
• (a) El-Deeb IM, Bayoumi SM, El-Sherbeny MA, et al. Synthesis and antitumor evaluation of novel cyclic arylsulfonylureas: ADME-T and pharmacophore prediction. Eur J Med Chem 2010;45:2516–30.
   PubMed Web of Science ®Google Scholar
  (b) Abdel-Aziz AAM, El-Azab AS, El-Subbagh HI, et al. Design, synthesis, single-crystal and preliminary antitumor activity of novel arenesulfonylimidazolidin-2-ones. Bioorg Med Chem Lett 2012;22:2008–14.
   PubMed Web of Science ®Google Scholar
  (c) Alanazi AM, El-Azab AS, Al-Swaidan IA, et al. Synthesis, single-crystal, in vitro antitumor evaluation and molecular docking of 3-substitued 5,5-diphenylimidazolidine-2,4-dione derivatives. Med Chem Res 2013;22:6129–42.
   Web of Science ®Google Scholar
• (a) Al-Suwaidan IA, Abdel-Aziz NI, El-Azab AS, et al. Antitumor evaluation and molecular docking study of substituted 2-benzylidenebutane-1,3-dione, 2-hydrazonobutane-1,3-dione and trifluoromethyl-1H-pyrazole analogues. J Enzyme Inhib Med Chem 2015;30:679–87.
   PubMed Web of Science ®Google Scholar
  (b) El-Sherbeny MA, Abdel-Aziz AAM, Ahmed MA. Synthesis and antitumor evaluation of novel diarylsulfonylurea derivatives: molecular modeling applications. Eur J Med Chem 2010;45:689–97.
   PubMed Web of Science ®Google Scholar
• (a) El-Husseiny WM, El-Sayed MAA, Abdel-Aziz NI, et al. Structural alterations based on naproxen scaffold: synthesis, evaluation of antitumor activity and COX-2 inhibition, and molecular docking. Eur J Med Chem 2018;158:134–43.
   PubMed Web of Science ®Google Scholar
  (b) El-Azab AS, Abdel-Aziz AAM, Abou-Zeid LA, et al. Synthesis, antitumour activities and molecular docking of thiocarboxylic acid ester-based NSAID scaffolds: COX-2 inhibition and mechanistic studies. J Enzyme Inhib Med Chem 2018;33:989–98.
   PubMed Web of Science ®Google Scholar
• El-Husseiny WM, El-Sayed MA, Abdel-Aziz NI, et al. Synthesis, antitumour and antioxidant activities of novel α,β-unsaturated ketones and related heterocyclic analogues: EGFR inhibition and molecular modelling study. J Enzyme Inhib Med Chem 2018;33:507–18.
   PubMed Web of Science ®Google Scholar
• El-Sayed MA, El-Husseiny WM, Abdel-Aziz NI, et al. Synthesis and biological evaluation of 2-styrylquinolines as antitumour agents and EGFR kinase inhibitors: molecular docking study. J Enzyme Inhib Med Chem 2018;33:199–209.
   PubMed Web of Science ®Google Scholar
• (a) Abdel-Aziz AAM, El-Azab AS, Alanazi AM, et al. Synthesis and potential antitumor activity of 7-(4-substituted piperazin-1-yl)-4-oxoquinolines based on ciprofloxacin and norfloxacin scaffolds: in silico studies. J Enzyme Inhib Med Chem 2016;31:796–809.
   PubMed Web of Science ®Google Scholar
  (b) Abdel-Aziz AAM, Asiri YA, Al-Agamy MH. Design, synthesis and antibacterial activity of fluoroquinolones containing bulky arenesulfonyl fragment: 2D-QSAR and docking study. Eur J Med Chem 2011;46:5487–97.
   PubMed Web of Science ®Google Scholar
• Bayomi SM, El-Kashef HA, El-Ashmawy MB, et al. Synthesis and biological evaluation of new curcumin analogues as antioxidant and antitumor agents: molecular modeling study. Eur J Med Chem 2015;101:584–94.
   PubMed Web of Science ®Google Scholar
• (a) Stanković T, Dinic J, Podolski-Renić A, et al. Dual inhibitors as a new challenge for cancer multidrug resistance treatment. Curr Med Chem 2019;26:6074–106.
   PubMed Web of Science ®Google Scholar
  (b) Raghavendra NM, Pingili D, Kadasi S, et al. Dual or multi-targeting inhibitors: the next generation anticancer agents. Eur J Med Chem 2018;143:1277–300.
   PubMed Web of Science ®Google Scholar
• (a) Dai ZJ, Ma XB, Kang HF, et al. Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in vitro and in vivo. Cancer Cell Int 2012;12:53.
   PubMed Web of Science ®Google Scholar
  (b) Ghosh N, Chaki R, Mandal V, et al. COX-2 as a target for cancer chemotherapy. Pharmacol Rep 2010;62:233–44.
   PubMed Web of Science ®Google Scholar
• (a) Blanke C. Role of COX-2 inhibitors in cancer therapy. Cancer Invest 2004;22:271–82.
   PubMed Web of Science ®Google Scholar
  (b) Basu GD, Pathangey LB, Tinder TL, et al. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 2005;7:422–35.
   PubMed Web of Science ®Google Scholar
• (a) Vosooghi M, Amini M. The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies. Expert Opin Drug Discov 2014;9:255–67.
   PubMed Web of Science ®Google Scholar
  (b) Claria J. Cyclooxygenase-2 biology. Curr Pharm Des 2003;9:2177–90.
   PubMed Web of Science ®Google Scholar
• Gurpinar E, Grizzle WE, Piazza GA. COX-independent mechanisms of cancer chemoprevention by anti-inflammatory drugs. Front Oncol 2013;3:181–18.
   PubMedGoogle Scholar
• (a) Hirsh L, Dantes A, Suh BS, et al. Phosphodiesterase inhibitors as anti-cancer drugs. Biochem Pharmacol 2004;68:981–8.
   PubMed Web of Science ®Google Scholar
  (b) Almatary AM, Elmorsy MA, El Husseiny WM, et al. Design, synthesis, and molecular modeling of heterocyclic bioisostere as potent PDE4 inhibitors. Arch Pharm (Weinheim) 2018;351:e1700403.
   PubMed Web of Science ®Google Scholar
  (c) Sandeep G, Bhasker S, Ranganath YS. Phosphodiesterase as a novel target in cancer chemotherapy. Int J Pharmacol 2009;7:1.
   Google Scholar
• (a) Drees M, Zimmermann R, Eisenbrand G. 3′,5′-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res 1993;53:3058–61.
   PubMed Web of Science ®Google Scholar
  (b) Savai R, Pullamsetti SS, Banat GA, et al. Targeting cancer with phosphodiesterase inhibitors. Expert Opin Investig Drugs 2010;19:117–31.
   PubMed Web of Science ®Google Scholar
• (a) Pullamsetti SS, Banat GA, Schmall A, et al. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF. Oncogene 2013;32:1121–34.
   PubMed Web of Science ®Google Scholar
  (b) Selige J, Hatzelmann A, Dunkern TJ. The differential impact of PDE4 subtypes in human lung fibroblasts on cytokine-induced proliferation and myofibroblast conversion. Cell Physiol 2011;226:1970–80.
   Web of Science ®Google Scholar
• (a) Domvri K, Zarogoulidis K, Ziogas N, et al. Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer. J Cancer 2017;8:3648–56.
   PubMed Web of Science ®Google Scholar
  (b) Yeo CD, Kim YA, Lee HY, et al. Roflumilast treatment inhibits lung carcinogenesis in benzo(a)pyrene-induced murine lung cancer model. Eur J Pharmacol 2017;812:189–95.
   PubMed Web of Science ®Google Scholar
• (a) Kim DU, Kwak B, Kim SW. Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer. Biochem Biophys Res Commun 2019;508:825–31.
   PubMed Web of Science ®Google Scholar
  (b) Tsunoda T, Ota T, Fujimoto T, et al. Inhibition of phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model. Mol Cancer 2012;11:46.
   PubMed Web of Science ®Google Scholar
• (a) Murata K, Sudo T, Kameyama M, et al. Cyclic AMP specific phosphodiesterase activity and colon cancer cell motility. Clin Exp Metastasis 2000;18:599–604.
   PubMed Web of Science ®Google Scholar
  (b) Nishi K, Luo H, Ishikura S, et al. Apremilast induces apoptosis of human colorectal cancer cells with mutant KRAS. Anticancer Res 2017;37:3833–9.
   PubMed Web of Science ®Google Scholar
• (a) Cooney JD, Aguiar RC. Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies. Blood 2016;128:2886–90.
   PubMed Web of Science ®Google Scholar
  (b) Kelly K, Mejia A, Suhasini AN, et al. Safety and pharmacodynamics of the PDE4 inhibitor roflumilast in advanced B-cell malignancies. Clin Cancer Res 2017;23:1186–92.
   PubMed Web of Science ®Google Scholar
• Kelly K, Mejia A, Suhasini AN, et al. Safety and pharmacodynamics of the PDE4 inhibitor roflumilast in advanced B-cell malignancies. Clin Cancer Res 2017;23:1186–92.
   PubMed Web of Science ®Google Scholar
• (a) Parikh N, Chakraborti AK. Phosphodiesterase 4 (PDE4) inhibitors in the treatment of COPD: promising drug candidates and future directions. Curr Med Chem 2016;23:129–41.
   PubMed Web of Science ®Google Scholar
  (b) Contreras S, Milara J, Morcillo E, et al. Selective inhibition of phosphodiesterases 4A, B, C and D isoforms in chronic respiratory diseases: current and future evidences. Curr Pharm Des 2017;23:2073–83.
   PubMed Web of Science ®Google Scholar
• Mouratidis PX, Colston KW, Bartlett JB, et al. Antiproliferative effects of CC-8062 and CC-8075 in pancreatic cancer cells. Pancreas 2009;38:78–84.
   PubMed Web of Science ®Google Scholar
• Balasubramanian G, Narayanan S, Andiappan L, et al. In vivo effective dibenzo[b,d]furan-1-yl-thiazoles as novel PDE-4 inhibitors. Bioorg Med Chem 2016;24:5702–16.
   PubMed Web of Science ®Google Scholar
• (a) Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor signalling: live or let die. Nat Rev Immunol 2015;15:362–74.
   PubMed Web of Science ®Google Scholar
  (b) Lebrec H, Ponce R, Preston BD, et al. Tumor necrosis factor, tumor necrosis factor inhibition, and cancer risk. Curr Med Res Opin 2015;31:557–74.
   PubMed Web of Science ®Google Scholar
• (a) Chuang MJ, Sun KH, Tang SJ, et al. Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial–mesenchymal transition in renal cell carcinoma cells. Cancer Sci 2008;99:905–13.
   PubMed Web of Science ®Google Scholar
  (b) Liu XL, Li FQ, Liu XL, et al. TNF-α, HGF and macrophage in peritumoural liver tissue relate to major risk factors of HCC recurrence. Hepatogastroenterology 2013;60:1121–6.
   PubMedGoogle Scholar
• (a) Mikami S, Mizuno R, Kosaka T, et al. Expression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomas. Int J Cancer 2015;136:1504–14.
   PubMed Web of Science ®Google Scholar
  (b) Zhu G, Du Q, Wang X, et al. TNF-α promotes gallbladder cancer cell growth and invasion through autocrine mechanisms. Int J Mol Med 2014;33:1431–40.
   PubMed Web of Science ®Google Scholar
• (a) Yu M, Zhou X, Niu L, et al. Targeting transmembrane TNF-α suppresses breast cancer growth. Cancer Res 2013;73:4061–74.
   PubMed Web of Science ®Google Scholar
  (b) Zidi I, Mestiri S, Bartegi A, et al. TNF-α and its inhibitors in cancer. Med Oncol 2010;27:185–98.
   PubMed Web of Science ®Google Scholar
• (a) Katsori AM, Hadjipavlou-Litina D. Chalcones in cancer: understanding their role in terms of QSAR. Curr Med Chem 2009;16:1062–81.
   PubMed Web of Science ®Google Scholar
  (b) Karthikeyan C, Moorthy N, Ramasamy S, et al. Advances in chalcones with anticancer activities. Recent Pat Anticancer Drug Discov 2014;10:97–115.
   Web of Science ®Google Scholar
• (a) Goel A, Boland CR, Chauhan DP. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 2001;172:111–8.
   PubMed Web of Science ®Google Scholar
  (b) Lev-Ari S, Strier D, Kazanov L, Madar-Shapiro L, et al. Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells. Clin Cancer Res 2005;11:6738–44.
   PubMed Web of Science ®Google Scholar
  (c) Lee SH, Lee GH, Park SY, et al. Apoptotic effects of curcumin via the regulation of COX-2/ VASP signaling molecules in MCF-7 breast cancer cells. Cancer Prev Res 2012;17:19–26.
   Google Scholar
• (a) Abusnina A, Keravis T, Zhou Q, et al. Tumour growth inhibition and anti-angiogenic effects using curcumin correspond to combined PDE2 and PDE4 inhibition. Thromb Haemost 2015;113:319–22.
   PubMed Web of Science ®Google Scholar
  (b) Abusnina A, Keravis T, Yougbaré I, et al. Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1. Mol Nutr Food Res 2011;55:1677–89.
   PubMed Web of Science ®Google Scholar
  (c) Yi YX, Gaurav A, Akowuah GA. Docking studies of curcumin and analogues with various phosphodiesterase 4 subtypes. Curr Drug Discov Technol 2018.
   PubMedGoogle Scholar
• Ahmed NM, Youns M, Soltan MK, et al. Design, synthesis, molecular modelling, and biological evaluation of novel substituted pyrimidine derivatives as potential anticancer agents for hepatocellular carcinoma. J Enzyme Inhib Med Chem 2019;34:1110–20.
   PubMed Web of Science ®Google Scholar
• Youssef KM, El-Sherbeny MA, El-Shafie FS, et al. Synthesis of curcumin analogues as potential antioxidant, cancer chemopreventive agents. Arch Pharm (Weinheim) 2004;337:42–54.
   PubMed Web of Science ®Google Scholar
• Kambe S, Saito K, Kishi H, et al. A one-step synthesis of 4-Oxo-2-thioxopyrimidine derivatives by the ternary condensation of ethyl cyanoacetate, aldehydes, and thiourea. Synthesis 1979;4:287.
   Google Scholar
• (a) Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. J Immunol Methods 1986;89:271–7.
   PubMed Web of Science ®Google Scholar
  (b) Vega-Avila E, Pugsley MK. An overview of colorimetric assay methods used to assess survival or proliferation of mammalian cells. West Pharmacol Soc 2011;54:10–4.
   PubMedGoogle Scholar
  (c) Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55–63.
   PubMed Web of Science ®Google Scholar
• (a) Abdel-Aziz AAM, Angeli A, El-Azab AS, et al. Synthesis and anti-inflammatory activity of sulfonamides and carboxylates incorporating trimellitimides: dual cyclooxygenase/carbonic anhydrase inhibitory actions. Bioorg Chem 2019;84:260–8.
   PubMed Web of Science ®Google Scholar
  (b) Uddin MJ, Rao PP, Knaus EE. Design and synthesis of acyclic triaryl (Z)-olefins: a novel class of cyclooxygenase-2 (COX-2) inhibitors. Bioorg Med Chem 2004;12:5929–40.
   PubMed Web of Science ®Google Scholar
  (c) El-Sayed MA, Abdel-Aziz NI, Abdel-Aziz AAM, et al. Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: molecular docking study. Bioorg Med Chem 2011;19:3416–24.
   PubMed Web of Science ®Google Scholar
  (d) El-Sayed MA, Abdel-Aziz NI, Abdel-Aziz AAM, et al. Synthesis, biological evaluation and molecular modeling study of pyrazole and pyrazoline derivatives as selective COX-2 inhibitors and anti-inflammatory agents. Part 2. Bioorg Med Chem 2012;20:3306–16.
   PubMed Web of Science ®Google Scholar
• (a) Abdel-Sayed MA, Bayomi SM, El-Sherbeny MA, et al. Synthesis, anti-inflammatory, analgesic, COX-1/2 inhibition activities and molecular docking study of pyrazoline derivatives. Bioorg Med Chem 2016;24:2032–42.
   PubMed Web of Science ®Google Scholar
  (b) Abdel-Aziz AAM, El-Azab AS, Abou-Zeid LA, et al. Synthesis, anti-inflammatory, analgesic and COX-1/2 inhibition activities of anilides based on 5,5-diphenylimidazolidine-2,4-dione scaffold: molecular docking studies. Eur J Med Chem 2016;115:121–31.
   PubMed Web of Science ®Google Scholar
• (a) Abdel-Aziz AAM, Abou-Zeid LA, ElTahir KEH, et al. Synthesis, anti-inflammatory, analgesic, COX-1/2 inhibitory activities and molecular docking studies of substituted 2-mercapto-4(3H)-quinazolinones. Eur J Med Chem 2016;121:410–21.
   PubMed Web of Science ®Google Scholar
  (b) Abdel-Aziz AAM, Abou-Zeid LA, ElTahir KE, et al. Design, synthesis of 2,3-disubstitued 4(3H)-quinazolinone derivatives as anti-inflammatory and analgesic agents: COX-1/2 inhibitory activities and molecular docking studies. Bioorg Med Chem 2016;24:3818–28.
   PubMed Web of Science ®Google Scholar
• Funakoshi-Tago M, Shimizu T, Tago K, et al. Celecoxib potently inhibits TNFα-induced nuclear translocation and activation of NF-κB. Biochem Pharmacol 2008;76:662–71.
   PubMed Web of Science ®Google Scholar
• Gupta M, Kaur G. Aqueous extract from the Withania somnifera leaves as a potential anti-neuroinflammatory agent: a mechanistic study. J Neuroinflammation 2016;13:193–209.
   PubMed Web of Science ®Google Scholar
• Molecular Operating Environment (MOE 2008.10) of Chemical Computing Group. Inc. Canada. Available from: http://www.chemcomp.com. 2008.
   Google Scholar
• El-Zahar MI, Abd El-Karim SS, Haiba ME. Synthesis and cytotoxic evaluation of some novel 6- (benzofuran-2-yl)-4-(4-fluorophenyl) pyridines. World J Chem 2008;4:182–194.
   Google Scholar
• (a) Davidson D, Weiss M, Jelling M. The action of ammonia on benzil. J Org Chem 1937;2:319–27.
   Google Scholar
  (b) Behmadi H, Roshani M, Saadati MS. Synthesis of phenanthrimidazole from 9,10-phenanthraquinone and aldehydes by molecular iodine as catalyst. Chin Chem Lett 2009;20:5–8.
   Web of Science ®Google Scholar
• Arshia P, Azim A, Shaikh KA. Ceric ammonium nitrate catalyzed efficient one-pot synthesis of 2, 4, 5-triarylimidazoles. Res J Pharm Biol Chem Sci 2010;1:943–951.
   Google Scholar
• Neelam PP, Rajesh HV, Hitesh SP. Ceric Ammonium Nitrate (CAN)–Catalyzed Multicomponent Reactions: An efficient catalyst for green organic synthesis. Synthetic Commun 2015;45:2399–2425.
   Google Scholar
• (a) Daniel LP, Carsten B. Recent advances in the Willgerodt-Kindler reaction. Chem Soc Rev 2013;42:7870–7880.
   Google Scholar
  (b) Aghapoor K, Mohsenazadeh F, Khanalizadeh G, et al. The Willgerodt-Kindler reaction in water: high chemoselectivity of benzaldehydes over acetophenones. Monatshefte Chem Chem Month 2007;138:61.
   Google Scholar
• (a) El-Zahar MI, Abd El-Karim SS, Haiba ME, et al. Synthesis, antitumor activity and molecular docking study of novel benzofuran-2-yl pyrazole pyrimidine derivatives. Acta Pol Pharm Drug Res 2011;68:357–73.
   PubMed Web of Science ®Google Scholar
  (b) Hussain SM, El‐Reedy AM, Hassan Rezk AM, et al. Reactions with 2-mercaptopyrimidines. Synthesis of some new thiazolo[3,2-a]- and triazolo[4,3-a]pyrimidines. J Heterocycl Chem 1987;24:1605–10.
   Web of Science ®Google Scholar
• (a) Al-Suwaidan IA, Alanazi AM, El-Azab AS, et al. Molecular design, synthesis and biological evaluation of cyclic imides bearing benzenesulfonamide fragment as potential COX-2 inhibitors. Part 2. Bioorg Med Chem Lett 2013;23:2601–5.
   PubMed Web of Science ®Google Scholar
  (b) Alanazi AM, El-Azab AS, Al-Suwaidan IA, et al. Structure-based design of phthalimide derivatives as potential cyclooxygenase-2 (COX-2) inhibitors: anti-inflammatory and analgesic activities. Eur J Med Chem 2015;92:115–23.
   PubMed Web of Science ®Google Scholar
  (c) Abdel-Aziz AAM, El Tahir KEH, Asiri YA. Synthesis, anti-inflammatory activity and COX-1/COX-2 inhibition of novel substituted cyclic imides. Part 1: molecular docking study. Eur J Med Chem 2011;46:1648–55.
   PubMed Web of Science ®Google Scholar
  (d) Abdel-Aziz AA, El-Azab AS, AlSaif NA, et al. Synthesis, anti-inflammatory, cytotoxic, and COX-1/2 inhibitory activities of cyclic imides bearing 3-benzenesulfonamide, oxime, and β-phenylalanine scaffolds: a molecular docking study. J Enzyme Inhib Med Chem 2020;35:610–21.
   PubMed Web of Science ®Google Scholar
• (a) El-Gamal MI, Bayomi SM, El-Ashry SM, et al. Synthesis and anti-inflammatory activity of novel (substituted)benzylidene acetone oxime ether derivatives: molecular modeling study. Eur J Med Chem 2010;45:1403–14.
   PubMed Web of Science ®Google Scholar
  (b) Goda FE, Abdel-Aziz AAM, Ghoneim HA. Synthesis and biological evaluation of novel 6-nitro-5-substituted aminoquinolines as local anesthetic and anti-arrhythmic agents: molecular modeling study. Bioorg Med Chem 2005;13:3175–83.
   PubMed Web of Science ®Google Scholar
  (c) Goda FE, Abdel-Aziz AAM, Attef OA. Synthesis, antimicrobial activity and conformational analysis of novel substituted pyridines: BF3-promoted reaction of hydrazine with 2-alkoxy pyridines. Bioorg Med Chem 2004;12:1845–52.
   PubMed Web of Science ®Google Scholar
  (d) El-Azab AS, Mary YS, Panicker CY, et al. DFT and experimental (FT-IR and FT-Raman) investigation of vibrational spectroscopy and molecular docking studies of 2-(4-oxo-3-phenethyl-3,4-dihydroquinazolin-2-ylthio)-N-(3,4,5-trimethoxyphenyl) acetamide. J Mol Struct 2016;1113:133–45.
   Web of Science ®Google Scholar
  (e) El-Azab AS, Abdel-Aziz AA, Ahmed HEA, et al. Exploring structure–activity relationship of S-substituted 2-mercaptoquinazolin-4(3H)-one including 4-ethylbenzenesulfonamides as human carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2020;35:598–609.
   PubMed Web of Science ®Google Scholar
• Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996;384:644–8.
   PubMed Web of Science ®Google Scholar
• Card GL, England BP, Suzuki Y, et al. Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure 2004;12:2233–47.
   PubMed Web of Science ®Google Scholar